Potential nephrotoxicity of intravenous infusions of naftidrofuryl oxalate. 1995

Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
Service de Néphrologie, Hôpital Dupuytren, Limoges, France.

We report two cases of acute renal failure in patients with arteriosclerosis obliterans treated by intravenous infusion of naftidrofuryl oxalate. At renal biopsy the histological lesions were identical with those found in ARF due to hyperoxaluria of other causes, revealing tubular epithelial necrosis and massive intratubular precipitation of calcium oxalate monohydrate (C1) crystals. A second study was then conducted in four other patients with arteriosclerosis obliterans to evaluate serum and urinary levels of oxalate, and crystalluria during the intravenous administration of 800 mg of naftidrofuryl oxalate per day for 10 days. During the course of treatment, the serum and urinary oxalate levels were found to increase substantially, with the gradual onset of massive C1 crystalluria. These results indicate that naftidrofuryl oxalate was responsible for the acute renal failure in the first two patients. High intravenous doses of naftidrofuryl oxalate must be used cautiously, with close surveillance of renal function.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009257 Nafronyl A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors. Nafronyloxalate,Naftidrofuryl,Artocoron,Azunaftil,Di-Actane,Dusodril,Gévatran,LS-121,Nafronyl Oxalate,Nafti Von Ct,Nafti-Puren,Nafti-Ratiopharm,Naftifurin Oxalate,Naftilong,Naftilux,Praxilene,Praxilène,Di Actane,LS 121,LS121,Nafti Puren,Nafti Ratiopharm,NaftiRatiopharm,Oxalate, Nafronyl,Oxalate, Naftifurin
D010070 Oxalates Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure. Oxalate,Ethanedioic Acids,Oxalic Acids,Acids, Ethanedioic,Acids, Oxalic
D002129 Calcium Oxalate The calcium salt of oxalic acid, occurring in the urine as crystals and in certain calculi. Calcium Oxalate (1:1),Calcium Oxalate Dihydrate,Calcium Oxalate Dihydrate (1:1),Calcium Oxalate Monohydrate,Calcium Oxalate Monohydrate (1:1),Calcium Oxalate Trihydrate,Dihydrate, Calcium Oxalate,Monohydrate, Calcium Oxalate,Oxalate, Calcium,Trihydrate, Calcium Oxalate
D003460 Crystallization The formation of crystalline substances from solutions or melts. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Crystalline Polymorphs,Polymorphism, Crystallization,Crystal Growth,Polymorphic Crystals,Crystal, Polymorphic,Crystalline Polymorph,Crystallization Polymorphism,Crystallization Polymorphisms,Crystals, Polymorphic,Growth, Crystal,Polymorph, Crystalline,Polymorphic Crystal,Polymorphisms, Crystallization,Polymorphs, Crystalline
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001162 Arteriosclerosis Obliterans Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION. Obliterans, Arteriosclerosis

Related Publications

Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
October 1977, British medical journal,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
June 2009, Metabolism: clinical and experimental,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
June 1977, British medical journal,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
July 1977, British medical journal,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
May 2000, Nephron,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
June 1977, British medical journal,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
November 1991, Lancet (London, England),
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
September 1973, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
November 1995, Age and ageing,
Y Le Meur, and C Moesch, and M Rincé, and J C Aldigier, and C Leroux-Robert
March 1977, The Journal of nutrition,
Copied contents to your clipboard!